Resmed Inc

RMD's recent bounce failed at the short-term EMAs, triggering a Bearish Pivot Point pattern that confirms upside control has deteriorated and price is set for structural repair lower. With price closing below the 9EMA and 20EMA—now sloping downward and crossing below the 50-day SMA—and no mean-reversion signal to the upside, the path of least resistance is down. Execution favors selling now into rallies at the short-term EMAs and the prior support-turned-resistance zone near the 50-day SMA.

• ↑Q4 FY26 revenue rose 9% YoY to $1.5B, non-GAAP EPS climbed 16% to $2.95.
• ↑Generated $1.6B free cash flow in FY26, supporting R&D and operations.
• ↓Class 1 FDA recall of Astral ventilators creates ~$75M revenue shortfall in FY27.